Clinical Trial Update: Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating atorvastatin 40 mg in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b; study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Betaseron (Interferon beta-1b)
• Lipitor (atorvastatin)

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED